Matthew W. Boudreau

Person

Urbana, IL, US

People

Patents Grantslast 30 patents

Information Patent Grant
Activators of the unfolded protein response
- Patent number 12,180,159
- Issue date Dec 31, 2024
- The Board of Trustees of the University of Illinois
- David J. Shapiro
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Cancer therapy by degrading dual MEK signaling
- Patent number 12,168,006
- Issue date Dec 17, 2024
- The Board of Trustees of the University of Illinois
- Paul J. Hergenrother
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Combination therapy for the treatment of uveal melanoma
- Patent number 12,090,153
- Issue date Sep 17, 2024
- The Board of Trustees of the University of Illinois
- Paul J. Hergenrother
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Activators of the unfolded protein response
- Patent number 11,584,718
- Issue date Feb 21, 2023
- The Board of Trustees of the University of Illinois
- David J. Shapiro
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Cancer therapy by degrading dual MEK signaling
- Patent number 11,510,919
- Issue date Nov 29, 2022
- The Board of Trustees of the University of Illinois
- Paul J. Hergenrother
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Activators of the unfolded protein response
- Patent number 11,046,647
- Issue date Jun 29, 2021
- The Board of Trustees of the University of Illinois
- David J. Shapiro
- C07 - ORGANIC CHEMISTRY

Patents Applicationslast 30 patents

Information Patent Application
ANTICANCER COMPOUNDS SELECTIVE FOR ER-POSITIVE CANCERS
- Publication number 20230391721
- Publication date Dec 7, 2023
- THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
- Paul J. HERGENROTHER
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
CANCER THERAPY BY DEGRADING DUAL MEK SIGNALING
- Publication number 20230158019
- Publication date May 25, 2023
- THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
- Paul J. HERGENROTHER
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
PROCASPASE-3 ACTIVATION AND IMMUNOTHERAPY FOR TREATMENT OF CANCER
- Publication number 20220226311
- Publication date Jul 21, 2022
- THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
- Paul J. HERGENROTHER
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
COMBINATION THERAPY FOR THE TREATMENT OF UVEAL MELANOMA
- Publication number 20220000862
- Publication date Jan 6, 2022
- THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
- Paul J. HERGENROTHER
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
ACTIVATORS OF THE UNFOLDED PROTEIN RESPONSE
- Publication number 20210340100
- Publication date Nov 4, 2021
- THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
- David J. SHAPIRO
- C07 - ORGANIC CHEMISTRY
Information Patent Application
ACTIVATORS OF THE UNFOLDED PROTEIN RESPONSE
- Publication number 20210276951
- Publication date Sep 9, 2021
- THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
- David J. SHAPIRO
- C07 - ORGANIC CHEMISTRY
Information Patent Application
CANCER THERAPY BY DEGRADING DUAL MEK SIGNALING
- Publication number 20200276189
- Publication date Sep 3, 2020
- The Board of Teustrrs of the University of Illinois
- Paul J. HERGENROTHER
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
ACTIVATORS OF THE UNFOLDED PROTEIN RESPONSE
- Publication number 20200190029
- Publication date Jun 18, 2020
- THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
- David J. SHAPIRO
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE

Matthew W. Boudreau

Person

Patents Grantslast 30 patents

Activators of the unfolded protein response

Cancer therapy by degrading dual MEK signaling

Combination therapy for the treatment of uveal melanoma

Activators of the unfolded protein response

Cancer therapy by degrading dual MEK signaling

Activators of the unfolded protein response

Patents Applicationslast 30 patents

ANTICANCER COMPOUNDS SELECTIVE FOR ER-POSITIVE CANCERS

CANCER THERAPY BY DEGRADING DUAL MEK SIGNALING

PROCASPASE-3 ACTIVATION AND IMMUNOTHERAPY FOR TREATMENT OF CANCER

COMBINATION THERAPY FOR THE TREATMENT OF UVEAL MELANOMA

ACTIVATORS OF THE UNFOLDED PROTEIN RESPONSE

ACTIVATORS OF THE UNFOLDED PROTEIN RESPONSE

CANCER THERAPY BY DEGRADING DUAL MEK SIGNALING

ACTIVATORS OF THE UNFOLDED PROTEIN RESPONSE